Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free HSAQ Stock Alerts

Health Sciences Acquisitions Co. 2 (HSAQ) Competitors

Health Sciences Acquisitions Co. 2 logo
$5.04 -0.15 (-2.80%)
As of 08/31/2026
Compare

HSAQ vs. STIM, ZJYL, PDEX, CNXU, and FOCL

Should you buy Health Sciences Acquisitions Co. 2 stock or one of its competitors? Health Sciences Acquisitions Co. 2's main competitors and comparable companies include Neuronetics (STIM), Jin Medical International (ZJYL), Pro-Dex (PDEX), Conexeu Sciences (CNXU), and FocalTherics (FOCL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Health Sciences Acquisitions Co. 2 compare to Neuronetics?

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Neuronetics (NASDAQ:STIM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Neuronetics' net margin of -19.62%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Neuronetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Health Sciences Acquisitions Co. 2N/A N/A -2.38%
Neuronetics -19.62%-125.11%-22.15%

Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Neuronetics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

In the previous week, Neuronetics had 2 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 2 mentions for Neuronetics and 0 mentions for Health Sciences Acquisitions Co. 2. Neuronetics' average media sentiment score of 1.86 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Neuronetics is being referred to more favorably in the news media.

Company Overall Sentiment
Health Sciences Acquisitions Co. 2 Neutral
Neuronetics Very Positive

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Neuronetics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A
Neuronetics$149.16M1.47-$39M-$0.44N/A

Neuronetics has a consensus price target of $4.50, indicating a potential upside of 55.98%. Given Neuronetics' stronger consensus rating and higher possible upside, analysts clearly believe Neuronetics is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Neuronetics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Comparatively, 8.4% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Neuronetics beats Health Sciences Acquisitions Co. 2 on 7 of the 13 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Jin Medical International?

Jin Medical International (NASDAQ:ZJYL) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

In the previous week, Jin Medical International had 2 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 2 mentions for Jin Medical International and 0 mentions for Health Sciences Acquisitions Co. 2. Jin Medical International's average media sentiment score of 0.30 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Jin Medical International is being referred to more favorably in the media.

Company Overall Sentiment
Jin Medical International Neutral
Health Sciences Acquisitions Co. 2 Neutral

Company Net Margins Return on Equity Return on Assets
Jin Medical InternationalN/A N/A N/A
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jin Medical International
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Jin Medical International has a beta of 7.33, meaning that its share price is 633% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Jin Medical International has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jin Medical International$20.69M8.90$1.19MN/AN/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

Summary

Jin Medical International beats Health Sciences Acquisitions Co. 2 on 7 of the 9 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Pro-Dex?

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Pro-Dex has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A
Pro-Dex$74.64M2.63$8.98M$3.6216.97

Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market.

Pro-Dex has a consensus price target of $70.00, indicating a potential upside of 13.97%. Given Pro-Dex's stronger consensus rating and higher probable upside, analysts plainly believe Pro-Dex is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Pro-Dex
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Comparatively, 45.9% of Pro-Dex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Pro-Dex had 3 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 3 mentions for Pro-Dex and 0 mentions for Health Sciences Acquisitions Co. 2. Pro-Dex's average media sentiment score of 0.62 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the news media.

Company Overall Sentiment
Health Sciences Acquisitions Co. 2 Neutral
Pro-Dex Positive

Pro-Dex has a net margin of 16.08% compared to Health Sciences Acquisitions Co. 2's net margin of 0.00%. Pro-Dex's return on equity of 22.78% beat Health Sciences Acquisitions Co. 2's return on equity.

Company Net Margins Return on Equity Return on Assets
Health Sciences Acquisitions Co. 2N/A N/A -2.38%
Pro-Dex 16.08%22.78%14.30%

Summary

Pro-Dex beats Health Sciences Acquisitions Co. 2 on 11 of the 13 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Conexeu Sciences?

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A
Conexeu SciencesN/AN/A-$3.92M-$0.11N/A

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Conexeu Sciences had 3 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 3 mentions for Conexeu Sciences and 0 mentions for Health Sciences Acquisitions Co. 2. Conexeu Sciences' average media sentiment score of 1.89 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Conexeu Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Health Sciences Acquisitions Co. 2 Neutral
Conexeu Sciences Very Positive

Conexeu Sciences has a consensus target price of $20.00, indicating a potential upside of 217.81%. Given Conexeu Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Conexeu Sciences is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Conexeu Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Company Net Margins Return on Equity Return on Assets
Health Sciences Acquisitions Co. 2N/A N/A -2.38%
Conexeu Sciences N/A N/A N/A

Summary

Conexeu Sciences beats Health Sciences Acquisitions Co. 2 on 6 of the 9 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to FocalTherics?

FocalTherics (NASDAQ:FOCL) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

FocalTherics has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to FocalTherics' net margin of -56.26%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat FocalTherics' return on equity.

Company Net Margins Return on Equity Return on Assets
FocalTherics-56.26% -248.00% -44.69%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

62.7% of FocalTherics shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 10.1% of FocalTherics shares are held by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

FocalTherics currently has a consensus target price of $7.75, suggesting a potential upside of 80.23%. Given FocalTherics' stronger consensus rating and higher possible upside, research analysts clearly believe FocalTherics is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FocalTherics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.40
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, FocalTherics had 15 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 15 mentions for FocalTherics and 0 mentions for Health Sciences Acquisitions Co. 2. FocalTherics' average media sentiment score of 0.78 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that FocalTherics is being referred to more favorably in the media.

Company Overall Sentiment
FocalTherics Positive
Health Sciences Acquisitions Co. 2 Neutral

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than FocalTherics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FocalTherics$70.53M2.29-$29.25M-$1.03N/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

Summary

FocalTherics and Health Sciences Acquisitions Co. 2 tied by winning 7 of the 14 factors compared between the two stocks.

Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically

Sign up to receive the latest news and ratings for HSAQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HSAQ vs. The Competition

Export
MetricHealth Sciences Acquisitions Co. 2Healthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$56.51M$5.70B$7.15B$12.76B
Dividend YieldN/A1.75%2.54%10.96%
P/E RatioN/A25.82272.3725.17
Price / SalesN/A71.37618.4597.60
Price / CashN/A33.6928.7836.03
Price / Book-8.136.2211.046.27
Net Income-$380K$148.55M$3.47B$348.97M
7 Day Performance-7.35%-1.09%-1.52%-1.95%
1 Month Performance26.63%6.13%7.32%3.46%
1 Year Performance84.62%5.77%23.96%14.18%

Health Sciences Acquisitions Co. 2 Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HSAQ
Health Sciences Acquisitions Co. 2
N/A$5.04
-2.8%		N/A+89.9%$56.51MN/AN/A4
STIM
Neuronetics
4.0442 of 5 stars		$3.00
+0.7%		$4.50
+50.0%		-14.7%$228.60M$149.16MN/A180
ZJYL
Jin Medical International
0.5628 of 5 stars		$2.79
+0.7%		N/A-83.7%$217.26M$19.73MN/A245
PDEX
Pro-Dex
1.7332 of 5 stars		$63.84
-2.1%		$70.00
+9.6%		+32.5%$203.84M$74.64M17.64140
CNXU
Conexeu Sciences
3.7309 of 5 stars		$6.97
-7.7%		$20.00
+186.9%		N/A$186.50MN/AN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HSAQ) was last updated on 9/1/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel